Amplia Therapeutics (Amplia Therapeutics) Net Change in Cash : $-3.93 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Amplia Therapeutics's Net Change in Cash for the six months ended in Sep. 2023 was $-2.31 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.93 Mil.

Amplia Therapeutics Net Change in Cash Historical Data

The historical data trend for Amplia Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Net Change in Cash Chart

Amplia Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Change in Cash

Get a 7-Day Free Trial

-0.70

-0.08

0.57

9.41

-3.57

Amplia Therapeutics Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Net Change in Cash	Get a 7-Day Free Trial															0.97	8.43	-1.95	-1.62	-2.31

Amplia Therapeutics Net Change in Cash Calculation

Amplia Therapeutics's Net Change in Cash for the fiscal year that ended in Mar. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-3.531	+	-0.039	+	-0.056	+	0.053
	=	-3.57

Amplia Therapeutics's Net Change in Cash for the quarter that ended in Sep. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -2.277 + 0 + -0.055 + 0.018

= -2.31

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-3.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Amplia Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Net Change in Cash

Comparable Companies

ASX:PAB ASX:IMC ASX:TRP ASX:ATH ASX:BTC ASX:IXC ASX:KZA ASX:CHM ASX:VBS ASX:1AI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
By PRNewswire • 01-18-2024

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
By PRNewswire PRNewswire • 05-29-2023

AACR OVARIAN CANCER CONFERENCE PRESENTATION
By PRNewswire • 10-09-2023